Source of Transplant Material in Autologous HSCT
In autologous hematopoietic stem cell transplantation, the transplant material comes from the patient's own body—specifically from their peripheral blood after mobilization with growth factors, or less commonly, from their bone marrow. 1
Primary Source: Mobilized Peripheral Blood
Peripheral blood is the preferred and predominant source of autologous stem cells for transplantation. 2 The process works as follows:
Mobilization Protocol
- G-CSF (filgrastim) at 10-32 mcg/kg/day is administered subcutaneously for 4-5 days to mobilize hematopoietic stem cells from the bone marrow into the peripheral blood 3
- Apheresis (collection) typically begins on day 4 or 5 3
- Alternative approach: G-CSF is given after chemotherapy (such as cyclophosphamide) during count recovery, starting approximately 24 hours after chemotherapy completion 3
Why Peripheral Blood Has Replaced Bone Marrow
The shift from bone marrow to peripheral blood as the primary source occurred because peripheral blood offers several critical advantages 1, 4:
- Faster hematologic recovery post-transplant
- Easier collection process via apheresis rather than bone marrow aspiration
- Avoids general anesthesia required for bone marrow harvest
- Reduced risk of graft failure
- Lower transplant-related mortality
Secondary Source: Bone Marrow
Bone marrow can still be harvested directly as an autologous source, though this is now uncommon 1. This requires:
- General anesthesia
- Direct aspiration from marrow-containing bones
- Longer recovery time
Minimum Cell Requirements
A minimum of 2×10⁶ CD34+ cells/kg must be collected to ensure prompt hematopoietic recovery following high-dose therapy 2. This threshold is critical for timely engraftment.
Critical Caveat: Avoiding Stem Cell Damage
Agents toxic to bone marrow stem cells (primarily melphalan and nitrosoureas) and large-volume radiation therapy to marrow-containing bones must be strictly avoided before stem cell collection 2. These can permanently damage the stem cell pool and compromise the ability to collect adequate cells for transplantation.
Enhanced Mobilization for Poor Mobilizers
For patients who fail to mobilize adequately with G-CSF alone, plerixafor (240 mcg/kg/day) can be added on day 4 of G-CSF treatment, given subcutaneously the evening before collection 3. This combination is particularly useful for:
- Heavily pretreated patients
- Those with risk factors for poor mobilization
- Failed prior collection attempts
- "Just in time" rescue when circulating CD34+ counts are below target
The evidence consistently demonstrates that peripheral blood has largely replaced bone marrow as the source of stem cells for autologous recipients 1, representing the current standard of care in autologous HSCT.